Skip to content
Home/Companies/Biotech/RoukenBio

RoukenBio

Biotech·United Kingdom·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns RoukenBio?

RoukenBio is a British Biotech company, currently owned by NorthEdge Capital since 2023.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
NorthEdge Capital
Investor
NorthEdge Capital
NorthEdge Fund III · 2020 · Buyout

Key facts

HQUnited Kingdom
SectorBiotech

More from NorthEdge Fund III

Other portfolio companies in the same fund.

Oak Engage
Oak Engage
Active
HR TechUK· 2025
Contollo
Contollo
Active
Business ServicesUK· 2024
Latus Group
Latus Group
Active
HealthcareUK· 2024
PebblePad
PebblePad
Active
EdTechUK· 2024
Torbay Pharmaceuticals
Torbay Pharmaceuticals
Active
PharmaUK· 2023
Friend MTS
Friend MTS
Active
CybersecurityUK· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns RoukenBio?

RoukenBio is currently owned by NorthEdge Capital, through NorthEdge Fund III, since 2023.

When did NorthEdge Capital acquire RoukenBio?

NorthEdge Capital acquired RoukenBio in 2023.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue